The agreement with Inex Pharmaceuticals provides access to fundamental liposome delivery technology for systemic RNAi therapeutics.
The agreement with the Massachusetts Institute of Technology (MIT) provides access to novel liposome technology being developed in the laboratory of Professor Robert Langer.
Alnylam recently announced the publication in the scientific journal Nature of the first demonstration of therapeutic gene silencing in primates with systemic RNAi using liposomal delivery technology.
“By taking advantage of the leadership of each company in its respective field, we expect this relationship to significantly accelerate the development of truly novel drugs for important diseases,” said Timothy Ruane, president and CEO of Inex.